enGene Therapeutics (S0N0) Stock Overview

Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. More details

S0N0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 64.27% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

S0N0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

enGene Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for enGene Therapeutics
Historical stock prices
Current Share Price	US$1.22
52 Week High	US$10.10
52 Week Low	US$1.02
Beta	-0.29
1 Month Change	-9.78%
3 Month Change	-80.03%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-83.84%

Recent updates

Shareholder Returns

	S0N0	DE Biotechs	DE Market
7D	-4.8%	2.9%	-0.7%
1Y	n/a	-6.3%	2.0%

Return vs Industry: Insufficient data to determine how S0N0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how S0N0 performed against the German Market.

Price Volatility

Is S0N0's price volatile compared to industry and market?
S0N0 volatility
S0N0 Average Weekly Movement	29.1%
Biotechs Industry Average Movement	8.9%
Market Average Movement	5.9%
10% most volatile stocks in DE Market	13.0%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: S0N0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: S0N0's weekly volatility has increased from 22% to 29% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	82	Ron Cooper	www.engene.com

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).

enGene Therapeutics Inc. Fundamentals Summary

How do enGene Therapeutics's earnings and revenue compare to its market cap?
S0N0 fundamental statistics
Market cap	€93.80m
Earnings (TTM)	-€105.82m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Is S0N0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
S0N0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$122.44m
Earnings	-US$122.44m

Last Reported Earnings

Jan 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.83
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	8.9%

How did S0N0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/14 02:08
End of Day Share Price	2026/06/12 00:00
Earnings	2026/01/31
Annual Earnings	2025/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

enGene Therapeutics Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jie Cheng	CGS International
Silvan Tuerkcan	Citizens JMP Securities, LLC
Michael Schmidt	Guggenheim Securities, LLC

enGene Therapeutics Inc.DB:S0N0 Stock Report